bioAffinity Technologies, Inc.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Sep 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.4M | $5.8M | $300.2K | $19.7K | $1.8M | $1.2K | $1.3K |
| Cost of Revenue | — | — | — | $74.7K | $1.2K | $87 | $146 | $146 |
| Gross Profit | — | — | — | $223.8K | $18.5K | $834 | $1.0K | $1.2K |
| Gross Margin | — | — | — | 74.5% | 93.7% | 0.0% | 87.3% | 88.8% |
| Operating Expenses | ||||||||
| Research & Development | $402.4K | $393.6K | $432.8K | $330.4K | $335.1K | $369.6K | $319.7K | $248.4K |
| SG&A Expense | $2.5M | $2.2M | $2.2M | $2.0M | $1.4M | $1.1M | $595.7K | $408.6K |
| Operating Income | $-2.1M | $-1.9M | $-2.3M | $-2.3M | $-1.8M | $-1.6M | $-976.2K | $-684.1K |
| Operating Margin | -87.1% | -80.8% | -40.6% | -764.2% | -9,009.8% | -86.3% | -84,883.1% | -52,382.8% |
| Interest Expense | — | $23.6K | $25.3K | $8.8K | $1.4K | $1.7K | $896.5K | $399.3K |
| Pretax Income | $-2.1M | $-2.0M | $-2.4M | $-2.3M | $-1.7M | $-1.5M | $-4.9M | $-88.1K |
| Income Tax Expense | $5.4K | $3.7K | $2.3K | $2.3K | $4.6K | $11.8K | $300 | — |
| Net Income | $-2.1M | $-2.0M | $-2.4M | $-2.3M | $-1.7M | $-1.5M | $-4.9M | $-88.1K |
| Net Margin | -88.0% | -81.5% | -41.1% | -763.0% | -8,816.4% | -84.9% | -427,779.0% | -6,742.1% |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.07 | $-0.07 | $-0.05 | $-0.05 | $-0.29 | $-0.01 |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.07 | $-0.07 | $-0.05 | $-0.05 | $-0.29 | $-0.01 |
| Shares Outstanding (Basic) | 45.6M | 39.7M | 35.0M | 34.8M | 34.1M | 33.7M | 16.8M | 10.8M |
| Shares Outstanding (Diluted) | 45.6M | 39.7M | 35.0M | 34.8M | 34.1M | 33.7M | 16.8M | 10.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |